OA11289A - Combination therapy comprising amlodipine and a statin compound. - Google Patents

Combination therapy comprising amlodipine and a statin compound. Download PDF

Info

Publication number: OA11289A
Authority: OA; OAPI
Prior art keywords: composition; pharmaceutically acceptable; statin; sait; daim
Prior art date: 1997-08-29

Application number

OA1200000038A

Other languages

English (en)

Inventor

Jan Buch

Robert Andrew Donald Scott

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-29

Filing date

2000-02-18

Publication date

2003-08-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11289(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-02-18 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-08-25 Publication of OA11289A publication Critical patent/OA11289A/en

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 168
229960000528 amlodipine Drugs 0.000 title claims abstract description 77
150000001875 compounds Chemical class 0.000 title claims description 35
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 3
238000002648 combination therapy Methods 0.000 title description 2
239000002253 acid Substances 0.000 claims abstract description 41
230000000747 cardiac effect Effects 0.000 claims abstract description 38
206010020772 Hypertension Diseases 0.000 claims abstract description 32
206010002383 Angina Pectoris Diseases 0.000 claims abstract description 30
239000000203 mixture Substances 0.000 claims description 231
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 185
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 185
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 185
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 145
239000008194 pharmaceutical composition Substances 0.000 claims description 125
FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims description 116
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 111
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 96
229960002965 pravastatin Drugs 0.000 claims description 96
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 96
229950009116 mevastatin Drugs 0.000 claims description 94
VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 claims description 91
VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 claims description 86
GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims description 86
VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 claims description 86
-1 fiuvastatin Chemical compound 0.000 claims description 80
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 73
230000000694 effects Effects 0.000 claims description 73
229960002855 simvastatin Drugs 0.000 claims description 73
229950003040 dalvastatin Drugs 0.000 claims description 70
VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 claims description 69
238000011282 treatment Methods 0.000 claims description 65
239000003085 diluting agent Substances 0.000 claims description 62
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 57
229960003765 fluvastatin Drugs 0.000 claims description 57
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 57
229960004844 lovastatin Drugs 0.000 claims description 57
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 57
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical group [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims description 45
241000124008 Mammalia Species 0.000 claims description 37
239000003937 drug carrier Substances 0.000 claims description 36
229960004005 amlodipine besylate Drugs 0.000 claims description 35
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 26
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 26
229960005370 atorvastatin Drugs 0.000 claims description 26
230000001225 therapeutic effect Effects 0.000 claims description 26
230000003257 anti-anginal effect Effects 0.000 claims description 18
230000003276 anti-hypertensive effect Effects 0.000 claims description 16
210000001715 carotid artery Anatomy 0.000 claims description 15
210000004351 coronary vessel Anatomy 0.000 claims description 14
230000002093 peripheral effect Effects 0.000 claims description 9
230000002411 adverse Effects 0.000 claims description 8
239000002552 dosage form Substances 0.000 claims description 6
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 3
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
230000001315 anti-hyperlipaemic effect Effects 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
238000000034 method Methods 0.000 abstract description 67
150000003839 salts Chemical class 0.000 abstract description 25
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract description 20
201000001320 Atherosclerosis Diseases 0.000 abstract description 5
239000000654 additive Substances 0.000 abstract description 4
230000000996 additive effect Effects 0.000 abstract description 4
208000024891 symptom Diseases 0.000 abstract description 4
239000011885 synergistic combination Substances 0.000 abstract description 4
208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
208000029078 coronary artery disease Diseases 0.000 description 20
239000003795 chemical substances by application Substances 0.000 description 12
239000012458 free base Substances 0.000 description 12
238000012360 testing method Methods 0.000 description 10
208000037260 Atherosclerotic Plaque Diseases 0.000 description 9
241000282412 Homo Species 0.000 description 9
150000002632 lipids Chemical class 0.000 description 9
230000000879 anti-atherosclerotic effect Effects 0.000 description 7
235000005911 diet Nutrition 0.000 description 7
230000037213 diet Effects 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
210000001367 artery Anatomy 0.000 description 6
230000007211 cardiovascular event Effects 0.000 description 6
238000002586 coronary angiography Methods 0.000 description 6
229940127291 Calcium channel antagonist Drugs 0.000 description 5
108010007622 LDL Lipoproteins Proteins 0.000 description 5
102000007330 LDL Lipoproteins Human genes 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000000480 calcium channel blocker Substances 0.000 description 5
238000002604 ultrasonography Methods 0.000 description 5
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 4
102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
208000019622 heart disease Diseases 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
238000011835 investigation Methods 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
230000000391 smoking effect Effects 0.000 description 4
239000002904 solvent Substances 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
108010010234 HDL Lipoproteins Proteins 0.000 description 3
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229910002651 NO3 Inorganic materials 0.000 description 3
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
229960005110 cerivastatin Drugs 0.000 description 3
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 3
239000006184 cosolvent Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 3
238000002651 drug therapy Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
150000004677 hydrates Chemical class 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
238000005259 measurement Methods 0.000 description 3
208000031225 myocardial ischemia Diseases 0.000 description 3
229940036132 norvasc Drugs 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
UHBVTTDRNVAOJD-UHFFFAOYSA-N 1-nitropropane-1,2,3-triol Chemical compound OCC(O)C(O)[N+]([O-])=O UHBVTTDRNVAOJD-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
208000020446 Cardiac disease Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
206010020880 Hypertrophy Diseases 0.000 description 2
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940030600 antihypertensive agent Drugs 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
239000003524 antilipemic agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
229960001231 choline Drugs 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000003205 diastolic effect Effects 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
229940043237 diethanolamine Drugs 0.000 description 2
239000000890 drug combination Substances 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
150000002596 lactones Chemical class 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
235000019371 penicillin G benzathine Nutrition 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
229960005141 piperazine Drugs 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
238000012216 screening Methods 0.000 description 2
241000894007 species Species 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
238000009662 stress testing Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000003325 tomography Methods 0.000 description 2
229960000281 trometamol Drugs 0.000 description 2
KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101150102415 Apob gene Proteins 0.000 description 1
241001553178 Arachis glabrata Species 0.000 description 1
235000017060 Arachis glabrata Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000018262 Arachis monticola Nutrition 0.000 description 1
239000004135 Bone phosphate Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000014882 Carotid artery disease Diseases 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010023302 HDL Cholesterol Proteins 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
102000004016 L-Type Calcium Channels Human genes 0.000 description 1
108090000420 L-Type Calcium Channels Proteins 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
201000001068 Prinzmetal angina Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
208000007718 Stable Angina Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
230000002253 anti-ischaemic effect Effects 0.000 description 1
229940124345 antianginal agent Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229960001714 calcium phosphate Drugs 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
238000011976 chest X-ray Methods 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
239000005516 coenzyme A Substances 0.000 description 1
229940093530 coenzyme a Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
235000001434 dietary modification Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000000916 dilatatory effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
SLFUXNFVAANERW-UHFFFAOYSA-N ethyl hexanoate;potassium Chemical compound [K].CCCCCC(=O)OCC SLFUXNFVAANERW-UHFFFAOYSA-N 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
229960000201 isosorbide dinitrate Drugs 0.000 description 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
229960003827 isosorbide mononitrate Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000004571 lime Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
238000010606 normalization Methods 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
230000004044 response Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
235000021003 saturated fats Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
238000011125 single therapy Methods 0.000 description 1
230000015590 smooth muscle cell migration Effects 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000004448 titration Methods 0.000 description 1
125000005490 tosylate group Chemical class 0.000 description 1
235000021076 total caloric intake Nutrition 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000021081 unsaturated fats Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Iron Core Of Rotating Electric Machines (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Electrotherapy Devices (AREA)

OA1200000038A 1997-08-29 2000-02-18 Combination therapy comprising amlodipine and a statin compound. OA11289A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5755597P	1997-08-29	1997-08-29

Publications (1)

Publication Number	Publication Date
OA11289A true OA11289A (en)	2003-08-25

Family

ID=22011309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000038A OA11289A (en)	1997-08-29	2000-02-18	Combination therapy comprising amlodipine and a statin compound.

Country Status (36)

Country	Link
US (1)	US20020025981A1 (es)
EP (1)	EP1003507A1 (es)
JP (1)	JP2001514224A (es)
KR (1)	KR20010022385A (es)
CN (1)	CN1117566C (es)
AP (1)	AP1207A (es)
AR (1)	AR017514A1 (es)
AU (1)	AU744982B2 (es)
BG (1)	BG104076A (es)
BR (1)	BR9811558A (es)
CA (1)	CA2296726C (es)
CO (1)	CO4970726A1 (es)
DZ (1)	DZ2600A1 (es)
EA (1)	EA002705B1 (es)
GT (1)	GT199800134A (es)
HN (1)	HN1998000124A (es)
HR (1)	HRP980475A2 (es)
HU (1)	HUP0003103A3 (es)
ID (1)	ID24275A (es)
IL (2)	IL133957A0 (es)
IS (1)	IS5345A (es)
MA (1)	MA26539A1 (es)
NO (1)	NO20000999L (es)
NZ (1)	NZ502283A (es)
OA (1)	OA11289A (es)
PA (1)	PA8457201A1 (es)
PE (1)	PE106999A1 (es)
PL (1)	PL339088A1 (es)
SA (1)	SA98190432A (es)
SK (1)	SK1392000A3 (es)
TN (1)	TNSN98158A1 (es)
TR (1)	TR200000562T2 (es)
UY (1)	UY25159A1 (es)
WO (1)	WO1999011263A1 (es)
YU (1)	YU2700A (es)
ZA (1)	ZA987843B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5830887A (en)	1992-05-19	1998-11-03	Novogen Research Pty. Ltd.	Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en)	1996-08-30	1996-09-26	Novogen Research Pty Ltd	Therapeutic uses
PT1140184E (pt)	1998-12-23	2003-10-31	Searle Llc	Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares
EP1076091A1 (en) *	1999-08-09	2001-02-14	Universite Catholique De Louvain	Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
AUPQ266199A0 (en)	1999-09-06	1999-09-30	Novogen Research Pty Ltd	Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) *	1999-09-20	2001-03-29	Bayer Ag	Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
CA2420844A1 (en) *	2000-08-30	2003-02-28	Sankyo Company, Limited	Medicinal compositions for preventing or treating heart failure
AUPR255401A0 (en) *	2001-01-16	2001-02-08	Novogen Research Pty Ltd	Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en)	2001-03-08	2001-04-05	Novogen Research Pty Ltd	Dimeric isoflavones
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
US6852753B2 (en)	2002-01-17	2005-02-08	Pharmacia Corporation	Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
NL1019882C2 (nl) *	2002-02-01	2003-08-04	Synthon Licensing	Amlodipine vrije base.
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
WO2005097191A2 (en) *	2004-04-04	2005-10-20	Sepracor Inc.	COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
KR100582347B1 (ko) *	2004-12-30	2006-05-22	한미약품 주식회사	3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100742432B1 (ko)	2005-12-27	2007-07-24	한미약품 주식회사	암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
CN101415425B (zh)	2006-03-29	2014-11-26	兴和株式会社	甘油三酯降低剂和高胰岛素血症改善剂
WO2008023958A1 (en) *	2006-08-24	2008-02-28	Hanall Pharmaceutical Co., Ltd.	Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) *	2006-08-24	2008-02-28	Hanall Pharmaceutical Co., Ltd.	Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
MX2007008440A (es) *	2007-07-11	2009-02-18	Senosiain S A De C V Lab	Composicion farmaceutica combinada.
KR20090091083A (ko) *	2008-02-22	2009-08-26	한올제약주식회사	방출성이 제어된 심혈관계질환 치료용 약제학적 제제
WO2009125987A2 (ko) *	2008-04-10	2009-10-15	한올제약주식회사	약제학적 제제
WO2010008203A2 (ko) *	2008-07-15	2010-01-21	한올제약주식회사	칼슘채널길항제를 포함하는 약제학적 제제
CN101804055B (zh) *	2010-04-27	2012-01-25	施慧达药业集团(吉林)有限公司	复方药物制剂
US20190263888A1 (en)	2010-10-19	2019-08-29	Op-T Llc	Therapeutic peptides and methods for treating autoimmune related disease
EP4035665A1 (en) *	2015-02-06	2022-08-03	Intercept Pharmaceuticals, Inc.	Pharmaceutical compositions for combination therapy
ES3031007T3 (en) *	2017-11-10	2025-07-03	Op T Llc	Peptide for preventing, modulating and/or reducing cardiovascular disease
US11793854B2 (en)	2019-03-21	2023-10-24	Op-T Llc	Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US12377045B2 (en)	2019-11-25	2025-08-05	Fordoz Pharma Corp.	Oral liquid formulations of lipid-lowering and blood pressure-lowering drugs
EP4135742A2 (en)	2020-04-17	2023-02-22	Op-T Llc	Bioactive peptides and methods of use thereof
CN112826937B (zh) *	2021-03-25	2022-03-22	山东大学齐鲁医院	艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IN176897B (es) *	1993-10-29	1996-09-28	Cadila Lab Ltd
DE19539363A1 (de) *	1995-10-23	1997-04-24	Basf Ag	Verfahren zur Herstellung von festen Arzneiformen

1998
- 1998-08-10 AP APAP/P/1998/001333A patent/AP1207A/en active
- 1998-08-10 YU YU2700A patent/YU2700A/sh unknown
- 1998-08-10 PL PL98339088A patent/PL339088A1/xx unknown
- 1998-08-10 BR BR9811558-8A patent/BR9811558A/pt not_active Application Discontinuation
- 1998-08-10 SK SK139-2000A patent/SK1392000A3/sk unknown
- 1998-08-10 IL IL13395798A patent/IL133957A0/xx unknown
- 1998-08-10 EP EP98935246A patent/EP1003507A1/en not_active Withdrawn
- 1998-08-10 NZ NZ502283A patent/NZ502283A/en unknown
- 1998-08-10 CN CN98808465A patent/CN1117566C/zh not_active Expired - Fee Related
- 1998-08-10 AU AU84585/98A patent/AU744982B2/en not_active Ceased
- 1998-08-10 WO PCT/IB1998/001220 patent/WO1999011263A1/en not_active Ceased
- 1998-08-10 EA EA200000013A patent/EA002705B1/ru not_active IP Right Cessation
- 1998-08-10 HU HU0003103A patent/HUP0003103A3/hu unknown
- 1998-08-10 ID IDW20000199A patent/ID24275A/id unknown
- 1998-08-10 KR KR1020007000964A patent/KR20010022385A/ko not_active Ceased
- 1998-08-10 CA CA002296726A patent/CA2296726C/en not_active Expired - Fee Related
- 1998-08-10 JP JP2000508366A patent/JP2001514224A/ja active Pending
- 1998-08-10 TR TR2000/00562T patent/TR200000562T2/xx unknown
- 1998-08-10 HN HN1998000124A patent/HN1998000124A/es unknown
- 1998-08-11 PA PA19988457201A patent/PA8457201A1/es unknown
- 1998-08-17 GT GT199800134A patent/GT199800134A/es unknown
- 1998-08-19 SA SA98190432A patent/SA98190432A/ar unknown
- 1998-08-24 PE PE1998000768A patent/PE106999A1/es not_active Application Discontinuation
- 1998-08-26 MA MA25231A patent/MA26539A1/fr unknown
- 1998-08-26 TN TNTNSN98158A patent/TNSN98158A1/fr unknown
- 1998-08-26 DZ DZ980210A patent/DZ2600A1/xx active
- 1998-08-27 UY UY25159A patent/UY25159A1/es not_active Application Discontinuation
- 1998-08-27 AR ARP980104289A patent/AR017514A1/es unknown
- 1998-08-27 CO CO98049137A patent/CO4970726A1/es unknown
- 1998-08-28 ZA ZA9807843A patent/ZA987843B/xx unknown
- 1998-08-28 HR HR60/057,555A patent/HRP980475A2/hr not_active Application Discontinuation
2000
- 2000-01-09 IL IL133957A patent/IL133957A/en unknown
- 2000-01-13 BG BG104076A patent/BG104076A/xx unknown
- 2000-01-14 IS IS5345A patent/IS5345A/is unknown
- 2000-02-18 OA OA1200000038A patent/OA11289A/en unknown
- 2000-02-28 NO NO20000999A patent/NO20000999L/no not_active Application Discontinuation
2001
- 2001-10-10 US US09/975,765 patent/US20020025981A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL133957A0 (en)	2001-04-30
NZ502283A (en)	2002-05-31
AR017514A1 (es)	2001-09-12
EA200000013A1 (ru)	2000-08-28
JP2001514224A (ja)	2001-09-11
DZ2600A1 (fr)	2003-03-01
CO4970726A1 (es)	2000-11-07
EA002705B1 (ru)	2002-08-29
IL133957A (en)	2006-06-11
ID24275A (id)	2000-07-13
AU744982B2 (en)	2002-03-07
HRP980475A2 (en)	1999-06-30
CA2296726A1 (en)	1999-03-11
ZA987843B (en)	2000-02-28
NO20000999D0 (no)	2000-02-28
EP1003507A1 (en)	2000-05-31
HK1029530A1 (en)	2001-04-06
CN1117566C (zh)	2003-08-13
US20020025981A1 (en)	2002-02-28
MA26539A1 (fr)	2004-12-20
AP9801333A0 (en)	1998-09-30
NO20000999L (no)	2000-02-28
SA98190432A (ar)	2005-12-03
YU2700A (sh)	2002-06-19
PE106999A1 (es)	1999-11-06
BG104076A (en)	2000-09-29
PA8457201A1 (es)	2000-05-24
AU8458598A (en)	1999-03-22
TR200000562T2 (tr)	2000-08-21
UY25159A1 (es)	2000-12-29
HN1998000124A (es)	1999-02-09
HUP0003103A2 (hu)	2001-01-29
CN1268054A (zh)	2000-09-27
AP1207A (en)	2003-09-20
BR9811558A (pt)	2000-08-22
GT199800134A (es)	2000-02-08
KR20010022385A (ko)	2001-03-15
WO1999011263A1 (en)	1999-03-11
SK1392000A3 (en)	2000-08-14
TNSN98158A1 (fr)	2005-03-15
PL339088A1 (en)	2000-12-04
CA2296726C (en)	2004-06-29
IS5345A (is)	2000-01-14
HUP0003103A3 (en)	2002-03-28

Publication	Publication Date	Title
OA11289A (en)	2003-08-25	Combination therapy comprising amlodipine and a statin compound.
AU755636B2 (en)	2002-12-19	Therapeutic combinations comprising amlodipin and atorvastatin
OA11951A (en)	2006-04-13	Mutual salt of amlodipine and atorvastatin.
EP1045691B1 (en)	2004-12-29	Statin-carboxyalkylether combinations
US20030092745A1 (en)	2003-05-15	Combination therapy
US8557835B2 (en)	2013-10-15	Statin-carboxyalkylether combinations
US20020103252A1 (en)	2002-08-01	Statin-carboxyalkylether combinations
MXPA00002085A (es)	2001-03-05	Terapia de combinacion